Adam Burgoyne

Photo of Adam Burgoyne
Title(s)Associate Clinical Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    A Phase I study of a dual PI3K/BRD4 inhibitor, SF1126 in the treatment of hepatocellular carcinoma IDE: 74,551
    NIH R01FD005113Sep 30, 2016 - Aug 31, 2020
    Role: Principal Investigator
    Collapse Clinical Trials

    Collapse Featured Content 

    Collapse Bibliographic 
    Collapse publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study. J Hepatol. 2026 Oct 06. Chan SL, Kudo M, Sangro B, Kelley RK, Kim JH, Pham B, Hong JY, Waldschmidt DT, Marino D, Gerolami R, Burgoyne AM, Masi G, Walsh RJ, Marquardt JU, Emeribe U, Balaji K, Sun P, Baur B, Rimassa L. PMID: 42838226.
      View in: PubMed   Mentions:
    2. NCCN Guidelines® Insights: Hepatocellular Carcinoma, Version 2.2026. J Natl Compr Canc Netw. 2026 Oct; 24(10). Benson AB, D'Angelica MI, Ahmed A, Akce M, Anaya DA, Anders R, Are C, Aye L, Bachini M, Baker M, Binder D, Burgoyne A, Castellanos J, Chokshi S, Cleary J, Cloyd J, Cullinan D, Dendy Case M, Franses J, Goyal L, Harris W, Jennings L, Kelley RK, Khan S, Krishnan M, Levine M, Melstrom L, Palta M, Raman S, Ronnekleiv-Kelly S, Sahai V, Stephans K, Thanikachalam K, Turk A, Vauthey JN, Venook AP, Wo J, Yano M, Yopp A, Zhao K, Schonfeld R, Stein M, Hochstetler C. PMID: 42874666.
      View in: PubMed   Mentions:
    3. Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies. Gut. 2026 Sep 24. Yarchoan M, Llovet JM, Kelley RK, Finn R, Parikh ND, Tabrizian P, Burgoyne AM, Agopian VG, Sanford NN, Tran Cao HS, Padia SA, Vogel A, Lewandowski RJ, Kirema GR, Lin R, Mehta N, Sapisochin G, Yopp A, Villanueva A, Halazun K, Pinato DJ, Kim E, Heimbach JK, Pillai A, Salem R, El-Khoueiry A, Singal AG. PMID: 42785981.
      View in: PubMed   Mentions:
    4. Preoperative Avapritinib for Localized PDGFRA-Mutant GIST: Marked Pathologic Response, but Limited Feasibility at Standard Dosing. Cancer Med. 2026 Aug; 15(8):e72100. Ranjbarian T, Antkowiak M, Sarno S, Kato S, Burgoyne AM, Mayo SC, Heinrich MC, Fanta PT, Sicklick JK. PMID: 42528110; PMCID: PMC13420325.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Radiographic Versus Pathology-Integrated Response for Assessing Optimal Surgical Timing After Neoadjuvant Imatinib in Patients With Locally Advanced KIT Exon 11-Mutant GIST. Ann Surg. 2026 09 01; 284(3):506-515. Ranjbarian T, Del Simone M, Kang Sim DE, Antkowiak M, Sarno S, Kato S, Burgoyne AM, Fumagalli ER, Callegaro D, Fanta PT, Gronchi A, Sicklick JK. PMID: 42440135.
      View in: PubMed   Mentions:    Fields:    
    6. Cytoreductive Surgery in Patients With Metastatic Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors. J Surg Oncol. 2026 Jun; 133(8):999-1006. Chen KY, Antkowiak M, Sharma AK, Mallory R, Burgoyne AM, Fanta PT, Sicklick JK. PMID: 42003827; PMCID: PMC13353120.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Characterization of Patients with Unresectable Hepatocellular Carcinoma in REFLECT Who Achieved Tumor Response or Alpha-Fetoprotein Response When Treated with Lenvatinib. Liver Cancer. 2026 Mar 05. Mahipal A, Cheng AL, Kudo M, Burgoyne A, Kalyan A, Lencioni R, Lopéz Lopéz C, Daniele B, Palmer DH, Baron AD, Park JW, Ren M, Mody K, Vogel A. PMID: 42111346; PMCID: PMC13155761.
      View in: PubMed   Mentions:
    8. Stoking an anti-liver cancer immune response with cryoablation plus an intratumoral TLR9 agonist and dual checkpoint inhibitors. Cancer Immunol Immunother. 2026 Feb 12; 75(3):74. Yang Y, Mandt T, Mittelstein D, Das M, Wu P, Ghani MA, Illindala R, Steinmetz NF, Burgoyne AM, Berman Z, Webster N, Newton IG. PMID: 41677856; PMCID: PMC12901810.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    9. Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis. Liver Cancer. 2025 Dec 18. Chan SL, Kudo M, Sangro B, Kelley RK, Kim JH, Pham B, Hong JY, Waldschmidt DT, Marino D, Joycelyn Lee JX, Gerolami R, Burgoyne AM, Li Q, Nakamura H, Sun P, Baur B, Rimassa L. PMID: 41585428; PMCID: PMC12830029.
      View in: PubMed   Mentions: 15  
    10. Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 09; 23(9):403-418. Benson AB, D'Angelica MI, Abrams T, Ahmed A, Akce M, Anaya DA, Anders R, Are C, Aye L, Bachini M, Baker M, Binder D, Brown DB, Burgoyne A, Castellanos J, Cloyd J, Cullinan D, Franses J, Glazer ES, Harris W, Iyer R, Jennings L, Kelley RK, Khan S, Levine M, Melstrom L, Palta M, Raman S, Ronnekleiv-Kelly S, Sahai V, Stein S, Stephans K, Thanikachalam K, Turk A, Vauthey JN, Venook AP, Yano M, Yopp A, Zhao K, Schonfeld R, Hochstetler C. PMID: 40930144.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    11. Hyperprogression and Systemic Metastasis of Cholangiocarcinoma after Histotripsy Therapy. J Vasc Interv Radiol. 2025 09; 36(9):1465-1466. Berman ZT, Patel T, Burgoyne AM, Clary BM. PMID: 40846437.
      View in: PubMed   Mentions: 1     Fields:    
    12. Blood microbial DNA signature differentiates hepatocellular carcinoma from metastatic lesions. eGastroenterology. 2025; 3(3):e100193. Guccione C, Dantas Machado AC, Youssef F, Angeli-Pahim I, Duarte S, Warren C, Farmer S, Humphrey G, Richter RA, McDonald D, Weng Y, Burgoyne A, Loomba R, Curtius K, Zarrinpar A, Knight R, Zarrinpar A. PMID: 40843454; PMCID: PMC12366555.
      View in: PubMed   Mentions:
    13. Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study. Lancet Oncol. 2025 Feb; 26(2):214-226. Finn RS, Ryoo BY, Hsu CH, Li D, Burgoyne AM, Cotter C, Badhrinarayanan S, Wang Y, Yin A, Edubilli TR, Mahrus S, Secrest MH, Shemesh CS, Yu N, Hack SP, Cha E, Gane E. PMID: 39855251.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    14. Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021). EClinicalMedicine. 2024 Jan; 67:102376. Li D, Loriot Y, Burgoyne AM, Cleary JM, Santoro A, Lin D, Aix SP, Garrido-Laguna I, Sudhagoni R, Guo X, Andrianova S, Paulson S. PMID: 38204489; PMCID: PMC10776423.
      View in: PubMed   Mentions: 5  
    15. NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023. J Natl Compr Canc Netw. 2023 07; 21(7):694-704. Benson AB, D'Angelica MI, Abrams T, Abbott DE, Ahmed A, Anaya DA, Anders R, Are C, Bachini M, Binder D, Borad M, Bowlus C, Brown D, Burgoyne A, Castellanos J, Chahal P, Cloyd J, Covey AM, Glazer ES, Hawkins WG, Iyer R, Jacob R, Jennings L, Kelley RK, Kim R, Levine M, Palta M, Park JO, Raman S, Reddy S, Ronnekleiv-Kelly S, Sahai V, Singh G, Stein S, Turk A, Vauthey JN, Venook AP, Yopp A, McMillian N, Schonfeld R, Hochstetler C. PMID: 37433432.
      View in: PubMed   Mentions: 115     Fields:    Translation:Humans
    16. Imaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives. Radiology. 2023 05; 307(3):e221429. Ronot M, Chernyak V, Burgoyne A, Chang J, Jiang H, Bashir M, Fowler KJ. PMID: 37014244.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    17. Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma. Oncologist. 2022 11 03; 27(11):e908-e911. Franses JW, Lim M, Burgoyne AM, Mody K, Lennerz J, Chang J, Imperial R, Dybel SN, Dinh TM, Masannat J, Weipert CM, Hsiehchen D. PMID: 36103364; PMCID: PMC9632309.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    18. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022 08; 28(8):1599-1611. Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. PMID: 35739268.
      View in: PubMed   Mentions: 354     Fields:    Translation:Humans
    19. Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy. Clin J Gastroenterol. 2021 Dec; 14(6):1718-1724. Dehghan Y, Schnickel GT, Hosseini M, Burgoyne AM, Ajmera VH, Morris GP, Mendler MH, Parekh JR, Abushamat F, Vodkin I, Kono Y. PMID: 34643885; PMCID: PMC8557174.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    20. Pathologic, Molecular, and Prognostic Radiologic Features of Hepatocellular Carcinoma. Radiographics. 2021 Oct; 41(6):1611-1631. Fowler KJ, Burgoyne A, Fraum TJ, Hosseini M, Ichikawa S, Kim S, Kitao A, Lee JM, Paradis V, Taouli B, Theise ND, Vilgrain V, Wang J, Sirlin CB, Chernyak V. PMID: 34597222.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    21. Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity. Clin Cancer Res. 2021 10 01; 27(19):5334-5342. Sharma AK, de la Torre J, IJzerman NS, Sutton TL, Zhao B, Khan TM, Banerjee S, Cui C, Nguyen V, Alkhuziem M, Snaebjornsson P, van Boven H, Bruining A, Tang CM, Yoon H, De la Fuente A, Kato S, Patel H, Heinrich MC, Corless CL, Horgan S, Burgoyne AM, Fanta P, Mesirov JP, Blakely AM, Davis JL, Mayo SC, van Houdt WJ, Steeghs N, Sicklick JK. PMID: 34326133; PMCID: PMC8799780.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    22. Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response. Clin Cancer Res. 2022 01 01; 28(1):187-200. Yebra M, Bhargava S, Kumar A, Burgoyne AM, Tang CM, Yoon H, Banerjee S, Aguilera J, Cordes T, Sheth V, Noh S, Ustoy R, Li S, Advani SJ, Corless CL, Heinrich MC, Kurzrock R, Lippman SM, Fanta PT, Harismendy O, Metallo C, Sicklick JK. PMID: 34426440; PMCID: PMC8738129.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    23. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 May 01; 19(5):541-565. Benson AB, D'Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, Bachini M, Borad M, Brown D, Burgoyne A, Chahal P, Chang DT, Cloyd J, Covey AM, Glazer ES, Goyal L, Hawkins WG, Iyer R, Jacob R, Kelley RK, Kim R, Levine M, Palta M, Park JO, Raman S, Reddy S, Sahai V, Schefter T, Singh G, Stein S, Vauthey JN, Venook AP, Yopp A, McMillian NR, Hochstetler C, Darlow SD. PMID: 34030131.
      View in: PubMed   Mentions: 551     Fields:    Translation:Humans
    24. Synchronous, Yet Genomically Distinct, GIST Offer New Insights Into Precise Targeting of Tumor Driver Mutations. JCO Precis Oncol. 2021; 5. Makris EA, Sharma AK, Bergstrom EN, Xu X, de la Torre J, Banerjee S, Nguyen V, Hosseini M, Burgoyne A, Harismendy O, Alexandrov LB, Sicklick JK. PMID: 34250403; PMCID: PMC8232556.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    25. Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis. Oncogene. 2021 03; 40(11):1957-1973. Yoon H, Tang CM, Banerjee S, Yebra M, Noh S, Burgoyne AM, Torre J, Siena M, Liu M, Klug LR, Choi YY, Hosseini M, Delgado AL, Wang Z, French RP, Lowy A, DeMatteo RP, Heinrich MC, Molinolo AA, Gutkind JS, Harismendy O, Sicklick JK. PMID: 33603171; PMCID: PMC7979540.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    26. Commission on Cancer Facility Type is Associated with Overall Survival in Patients with Gastric Adenocarcinoma in the United States. Ann Surg Oncol. 2021 May; 28(5):2846-2855. Banerjee S, Zhao B, Sicklick JK, Aslam S, Burgoyne AM, Kelly KJ. PMID: 33389292.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. Int J Cancer. 2021 02 01; 148(3):702-712. Okamura R, Kurzrock R, Mallory RJ, Fanta PT, Burgoyne AM, Clary BM, Kato S, Sicklick JK. PMID: 32700810; PMCID: PMC7739197.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    28. A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity. Cell Discov. 2020; 6(1):49. Burgoyne AM, Vann KR, Joshi S, Morales GA, Vega FM, Singh A, Pal D, Merati AB, Kutateladze TG, Durden DL. PMID: 32793389; PMCID: PMC7385619.
      View in: PubMed   Mentions: 9  
    29. Design of thienopyranone-based BET inhibitors that bind multiple synthetic lethality targets. Sci Rep. 2020 07 21; 10(1):12027. Vann KR, Pal D, Morales GA, Burgoyne AM, Durden DL, Kutateladze TG. PMID: 32694708; PMCID: PMC7374098.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    30. Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors. Cancer Metastasis Rev. 2019 09; 38(3):525-535. Neppala P, Banerjee S, Fanta PT, Yerba M, Porras KA, Burgoyne AM, Sicklick JK. PMID: 31773431; PMCID: PMC6903702.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimals
    31. Loss of the PTCH1 tumor suppressor defines a new subset of plexiform fibromyxoma. J Transl Med. 2019 07 30; 17(1):246. Banerjee S, Corless CL, Miettinen MM, Noh S, Ustoy R, Davis JL, Tang CM, Yebra M, Burgoyne AM, Sicklick JK. PMID: 31362756; PMCID: PMC6668176.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    32. Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: Retrospective analysis of an International Patient Registry. J Surg Oncol. 2019 Sep; 120(4):715-721. Stuart E, Banerjee S, de la Torre J, Wang Y, Scherzer N, Burgoyne AM, Parry L, Fanta PT, Ramamoorthy S, Sicklick JK. PMID: 31297829; PMCID: PMC6699886.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    33. Gastric Plexiform Fibromyxoma. J Gastrointest Surg. 2019 09; 23(9):1936-1939. Banerjee S, de la Torre J, Burgoyne AM, Ponsford Tipps AM, Savides TJ, Sicklick JK. PMID: 30761468; PMCID: PMC6692254.
      View in: PubMed   Mentions: 3     Fields:    
    34. Tumor Symbiosis: Gastrointestinal Stromal Tumor as a Host for Primary Peritoneal Mesothelioma. J Gastrointest Surg. 2019 04; 23(4):879-881. de la Torre J, Banerjee S, Baumgartner J, Lin GY, Burgoyne AM, Kirane A, Sicklick J. PMID: 30132292; PMCID: PMC6384158.
      View in: PubMed   Mentions: 4     Fields:    
    35. A Novel PRKAR1B-BRAF Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy. J Natl Compr Canc Netw. 2018 03; 16(3):238-242. Charo LM, Burgoyne AM, Fanta PT, Patel H, Chmielecki J, Sicklick JK, McHale MT. PMID: 29523662; PMCID: PMC6053908.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    36. Duodenal-Jejunal Flexure GI Stromal Tumor Frequently Heralds Somatic NF1 and Notch Pathway Mutations. JCO Precis Oncol. 2017; 2017. Burgoyne AM, De Siena M, Alkhuziem M, Tang CM, Medina B, Fanta PT, Belinsky MG, von Mehren M, Thorson JA, Madlensky L, Bowler T, D'Angelo F, Stupack DG, Harismendy O, DeMatteo RP, Sicklick JK. PMID: 29938249; PMCID: PMC6013064.
      View in: PubMed   Mentions: 14     Fields:    
    37. The Call of "The Wild"-Type GIST: It's Time for Domestication. J Natl Compr Canc Netw. 2017 05; 15(5):551-554. Alkhuziem M, Burgoyne AM, Fanta PT, Tang CM, Sicklick JK. PMID: 28476734; PMCID: PMC5549855.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    38. FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. J Transl Med. 2016 12 14; 14(1):339. Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, Corless CL, Hong D, Fero KE, Murphy JD, Fanta PT, Ali SM, De Siena M, Burgoyne AM, Movva S, Madlensky L, Heestand GM, Trent JC, Kurzrock R, Morosini D, Ross JS, Harismendy O, Sicklick JK. PMID: 27974047; PMCID: PMC5157084.
      View in: PubMed   Mentions: 119     Fields:    Translation:Humans
    39. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression. Oncotarget. 2016 Nov 29; 7(48):78226-78241. Tang CM, Lee TE, Syed SA, Burgoyne AM, Leonard SY, Gao F, Chan JC, Shi E, Chmielecki J, Morosini D, Wang K, Ross JS, Kendrick ML, Bardsley MR, Siena M, Mao J, Harismendy O, Ordog T, Sicklick JK. PMID: 27793025; PMCID: PMC5346634.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    40. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Mol Cancer Ther. 2016 11; 15(11):2553-2562. Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL. PMID: 27496136; PMCID: PMC5278767.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    41. Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study. Cancer. 2015 Sep 01; 121(17):2960-7. Murphy JD, Ma GL, Baumgartner JM, Madlensky L, Burgoyne AM, Tang CM, Martinez ME, Sicklick JK. PMID: 25930983; PMCID: PMC4545693.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    42. Gastrointestinal stromal tumors in the setting of multiple tumor syndromes. Curr Opin Oncol. 2014 Jul; 26(4):408-14. Burgoyne AM, Somaiah N, Sicklick JK. PMID: 24840526.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    43. Molecular phylogeny of Pholadoidea Lamarck, 1809 supports a single origin for xylotrophy (wood feeding) and xylotrophic bacterial endosymbiosis in Bivalvia. Mol Phylogenet Evol. 2011 Nov; 61(2):245-54. Distel DL, Amin M, Burgoyne A, Linton E, Mamangkey G, Morrill W, Nove J, Wood N, Yang J. PMID: 21684342.
      View in: PubMed   Mentions: 27     Fields:    Translation:AnimalsCells
    44. A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase mu. Neoplasia. 2010 Apr; 12(4):305-16. Burden-Gulley SM, Gates TJ, Burgoyne AM, Cutter JL, Lodowski DT, Robinson S, Sloan AE, Miller RH, Basilion JP, Brady-Kalnay SM. PMID: 20360941; PMCID: PMC2847738.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    45. PTPmu suppresses glioma cell migration and dispersal. Neuro Oncol. 2009 Dec; 11(6):767-78. Burgoyne AM, Palomo JM, Phillips-Mason PJ, Burden-Gulley SM, Major DL, Zaremba A, Robinson S, Sloan AE, Vogelbaum MA, Miller RH, Brady-Kalnay SM. PMID: 19304959; PMCID: PMC2802397.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimals
    46. Proteolytic cleavage of protein tyrosine phosphatase mu regulates glioblastoma cell migration. Cancer Res. 2009 Sep 01; 69(17):6960-8. Burgoyne AM, Phillips-Mason PJ, Burden-Gulley SM, Robinson S, Sloan AE, Miller RH, Brady-Kalnay SM. PMID: 19690139; PMCID: PMC2747800.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimalsCells
    47. CelAB, a multifunctional cellulase encoded by Teredinibacter turnerae T7902T, a culturable symbiont isolated from the wood-boring marine bivalve Lyrodus pedicellatus. Appl Environ Microbiol. 2007 Dec; 73(23):7785-8. Ekborg NA, Morrill W, Burgoyne AM, Li L, Distel DL. PMID: 17933945; PMCID: PMC2168062.
      View in: PubMed   Mentions: 23     Fields:    Translation:AnimalsCells
    Adam's Networks
    Concepts (209)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (67)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-64-g4ee1c7b9 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California